If management are working in the interest of shareholders, I wonder what the next move would be. Progress with EMA approved phase III trial or continue trying to harmonise studies leading to delay of progress and likely reduction of SP.
The shorter term part of me hopes progress with EMA trial and stop the share price bleeding and continue discussions with FDA in parallel. Partner with big pharma with EMA progress/results then head to the FDA with a big tailwind. An answer by mid July I would expect.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
9.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.763M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 42086 | 8.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.7¢ | 9000 | 1 |
View Market Depth
| Last trade - 16.21pm 21/07/2025 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable